MW
ALNY icon

Milestone Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Milestone Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$10K Hold
49
– – 0.01% 171
2022
Q2 		$7K Hold
49
– – 0.01% 181
2022
Q1 		$8K Hold
49
– – 0.01% 209
2021
Q4 		$8K Buy
+49
New +$9.11K 0.01% 209

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Milestone Wealth's ALNY Position: Q3 2022 in Review

Milestone Wealth held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2022 at 49 shares worth $10K. The position accounts for 0.01% of the portfolio, ranked #171.

Milestone Wealth first reported a position in ALNY in Q4 2021 and has held it in 4 quarters since. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Milestone Wealth held 49 shares of Alnylam Pharmaceuticals worth $10K as of Q3 2022.
  • Milestone Wealth left its Alnylam Pharmaceuticals share count unchanged in Q3 2022.
  • Alnylam Pharmaceuticals made up 0.01% of Milestone Wealth's portfolio in Q3 2022, its #171 holding.
  • Milestone Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Milestone Wealth's 13F filing for Q3 2022, filed 14 Nov 2022.